- Home
- EVAX vs SNGX Comparison
EVAX vs SNGX Comparison
Compare EVAX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- SNGX
- Stock Information
- Founded
- EVAX 2008
- SNGX 1987
- Country
- EVAX Denmark
- SNGX United States
- Employees
- EVAX N/A
- SNGX N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- SNGX Health Care
- Exchange
- EVAX Nasdaq
- SNGX Nasdaq
- Market Cap
- EVAX 16.3M
- SNGX 6.1M
- IPO Year
- EVAX 2021
- SNGX 1987
- Fundamental
- Price
- EVAX $1.79
- SNGX $2.30
- Analyst Decision
- EVAX Strong Buy
- SNGX
- Analyst Count
- EVAX 3
- SNGX 0
- Target Price
- EVAX $33.33
- SNGX N/A
- AVG Volume (30 Days)
- EVAX 211.9K
- SNGX 30.0K
- Earning Date
- EVAX 03-26-2025
- SNGX 03-21-2025
- Dividend Yield
- EVAX N/A
- SNGX N/A
- EPS Growth
- EVAX N/A
- SNGX N/A
- EPS
- EVAX N/A
- SNGX N/A
- Revenue
- EVAX $3,295,000.00
- SNGX $364,183.00
- Revenue This Year
- EVAX $9,039.73
- SNGX N/A
- Revenue Next Year
- EVAX $1.47
- SNGX $119.78
- P/E Ratio
- EVAX N/A
- SNGX N/A
- Revenue Growth
- EVAX N/A
- SNGX N/A
- 52 Week Low
- EVAX $1.70
- SNGX $1.83
- 52 Week High
- EVAX $22.05
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- EVAX 35.07
- SNGX 45.88
- Support Level
- EVAX $1.75
- SNGX $2.21
- Resistance Level
- EVAX $1.99
- SNGX $2.32
- Average True Range (ATR)
- EVAX 0.17
- SNGX 0.12
- MACD
- EVAX 0.05
- SNGX 0.02
- Stochastic Oscillator
- EVAX 10.70
- SNGX 50.00
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).